多囊性肾病变治疗市场按药物类型、给药途径、疾病类型、通路和最终用户划分－2025-2032年全球预测

预计到 2032 年，多囊性肾病治疗市场将成长至 7.8219 亿美元，复合年增长率为 4.75%。

为多囊性肾病变的治疗方法制定清晰权威的框架，涵盖治疗进展、相关人员的期望和临床优先事项。

多囊性肾病变是一个临床复杂且商业性动态变化的领域，机制理解、治疗研发和医疗服务等方面的进展正在不断融合。近年来，该领域的治疗已从症状治疗转向标靶治疗，旨在透过深入了解囊肿形成、细胞内信号通路和肾臟血流动力学来改变疾病进展。这一发展趋势提高了製药公司、生技公司、支付方和医疗保健系统面临的挑战，他们需要应对新的证据、监管里程碑和患者的期望。

目前的治疗环境呈现出治疗方式和临床终点指标的异质性，这要求相关人员整合来自不同试验设计和真实世界结果指标的证据。同时，诊断和生物标记的进步使得患者能够更早被识别和分层，从而影响临床决策和试验入组策略。临床医生越来越重视个人化治疗方案，这些方案旨在长期保护肾臟功能，同时兼顾疗效、安全性和生活品质。

从行业角度来看，标靶药物的引入正将商业性对话的焦点转向专科药物销售、与支付方的谈判以及患者用药项目。这种转变正在催生药物研发者、医疗系统和病患权益组织之间的新合作模式。因此，策略规划必须考虑临床差异化、供应链韧性和实证医学，以支持与整个医疗服务链中的相关人员进行基于价值的对话。

科学突破、适应性监管环境和趋同的竞争格局如何重新定义治疗领域的竞争和临床优先事项

在科学创新、监管环境日益清晰以及以持久疗效为优先的商业化策略的推动下，多囊性肾病变的治疗格局正在改变。分子标靶治疗和通路特异性介入的突破性进展正在拓展治疗套件，并推动治疗策略从广泛的症状治疗转向以减缓囊肿生长和保护肾功能为重点的缓解疾病疗法。因此，临床研发路径也变得更加复杂，更加重视替代标记、长期终点和患者报告结局，以全面了解新治疗方法的多方面益处。

随着科学的进步，监管机构也展现出对新型终点指标和适应性试验设计的开放态度，加速了领先候选药物的研发路径优化。这些监管变革，加上支付方对与疗效挂钩的报销模式的关注，正促使生物製药企业製定综合性的证据生成计划，包括核准后的真实世界临床试验。此外，市场也见证了策略伙伴关係关係的拓展，这些合作关係将发现阶段的创新与后期开发和商业化能力相结合，从而实现更快的规模化生产和更广泛的地域覆盖。

在营运层面，向专科药物和口服药物的转变正在重塑分销模式和病患支援基础设施。製造商正在完善患者援助计划、枢纽服务和数位依从性解决方案，以支持长期照护计划。这些转变正在重新定义竞争格局，并提升差异化临床特征和综合支持服务的重要性，以确保患者能够获得治疗并维持治疗。

评估近期关税政策调整如何重塑整个医药价值链的筹资策略、供应链韧性和采购重点。

美国公布的2025年关税政策为製药企业和经销商的供应链规划和采购成本建模带来了新的挑战。成品药通常适用特定的贸易分类，但针对活性药物成分、原料和中间体化学品的关税及相关进口措施会增加投入成本，并使筹资策略更加复杂。因此，製造商正在重新评估其供应商布局，评估产品系列的关税风险，并进行情境规划，以保障生产连续性免受贸易中断的影响。

为因应这项挑战，业内相关人员正加速推动采购多元化，减少对特定地区的依赖，尽可能提高在地采购，并与委託製造生产商协商条款以应对价格波动。这些调整也推动了对近岸外包和双重采购策略的投资，以提高供应链的透明度和反应速度。此外，关税带来的成本压力可能会影响与支付方和医疗系统的定价谈判，尤其是在利润率控制较为高成本专科疗法领域。

除了直接的成本影响外，关税还促使各方展开更广泛的战略对话，包括关键原料药和包装材料的本土产能、监管协调以及公私合营，以保护重要的药品供应链。因此，上市公司也积极游说，争取关税豁免和政策放宽，他们既认识到供应链中断对公众健康的影响，又需要在资源投入的经济效益与扩大国内生产规模所需的资金和时间之间取得平衡。简言之，2025年的关税情势凸显了整个产业采用弹性采购模式和积极参与政策制定的必要性。

基于多维细分的分析揭示了临床差异、通路和医疗保健环境如何创造策略机会和营运要务。

本研究揭示了不同药物类别、给药途径、疾病表型、通路和医疗环境中的差异化机会和营运要务。按药物类型划分，本研究分析了血管收缩素II受体阻断剂、血管收缩素转化酵素抑制剂、钙通道阻断剂、mTOR抑制剂、生长抑制素类似物和血管加压素受体拮抗剂，每种药物的作用机制、安全性特征和研发轨迹均不相同，这些因素会影响其市场定位和临床效用。基于给药方式，本研究区分了输注或註射疗法和口服疗法，重点分析了患者依从性、输注基础设施需求和报销机制方面的差异。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 在临床前试验中，越来越多地使用基因编辑技术（例如 CRISPR）来修正 PKD1 和 PKD2 突变。
• 越来越多的临床试验正在探索针对 mTOR 和 cAMP 讯号路径联合治疗在 ADPKD 治疗的应用。
• 数位健康平台在多囊性肾病变患者肾功能远端监测的应用进展
• 拓展基于生物标记的患者分层方法，以实现ADPKD的个人化治疗方法
• 监管机构加速核准核准为孤儿药的新型多囊性肾病变治疗药物
• 增加对多半胱氨酸蛋白转运小分子调变器的投资，以抑制囊肿生长
• 支持长期服用托伐普坦治疗ADPKD的安全性和有效性的真实世界临床证据开始被利用。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 多囊性肾病变治疗药物市场（依药物类型划分）

• 血管收缩素II受体阻断剂
• 血管收缩素转化酵素抑制剂
• 钙通道阻断剂
• mTOR抑制剂
• 生长抑制素类似物
• 血管加压素受体拮抗剂

9. 多囊性肾病变治疗药物市场（依剂型划分）

• 静脉注射注射或註射
• 口服

第十章 多囊性肾病药物市场（依疾病类型划分）

• 常染色体显性多囊性肾病变
• 常染色体隐性多囊性肾病变

第十一章 多囊性肾病药物市场（依通路划分）

• 医院药房
• 网路药房
• 零售药房

第十二章 多囊性肾病治疗市场（依最终用户划分）

• 诊所
• 居家照护
• 医院

13. 多囊性肾病药物市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 多囊性肾病药物市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国多囊性肾病药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Apotex Inc.
  • Boehringer Ingelheim GmbH
  • Centessa Pharmaceuticals Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Galapagos NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

The Polycystic Kidney Disease Drugs Market is projected to grow by USD 782.19 million at a CAGR of 4.75% by 2032.

A clear and authoritative framing of therapeutic advances, stakeholder expectations, and clinical priorities reshaping treatment approaches for polycystic kidney disease

Polycystic kidney disease remains a clinically complex and commercially dynamic area where advances in mechanistic understanding, therapeutic development, and care delivery are converging. In recent years, the field has moved beyond symptomatic management to targeted therapies that aim to modify disease progression, informed by deeper insights into cystogenesis, intracellular signaling pathways, and renal hemodynamics. This evolution has elevated the stakes for pharmaceutical and biotech organizations, payers, and health systems alike, as they navigate new evidence, regulatory milestones, and patient expectations.

The current therapeutic environment features heterogeneity in treatment modalities and clinical endpoints, which requires stakeholders to synthesize evidence across diverse trial designs and real-world outcome measures. Simultaneously, advancements in diagnostics and biomarkers are enabling earlier identification and stratification of patients, which influences clinical decision making and trial enrollment strategies. Clinicians are becoming more attuned to individualized treatment plans that balance efficacy, safety, and quality-of-life considerations while addressing long-term renal preservation.

From an industry perspective, the introduction of targeted agents has shifted commercial conversations toward specialty distribution, payer negotiations, and patient access programs. These shifts are creating new models for collaboration between developers, health systems, and patient advocacy organizations. As a result, strategic planning must account for clinical differentiation, supply chain resilience, and evidence generation that supports value-based conversations with stakeholders across the care continuum.

How scientific breakthroughs, adaptive regulatory frameworks, and integrated commercialization strategies are redefining competitive and clinical priorities in the therapeutic landscape

The landscape for polycystic kidney disease therapeutics is undergoing transformative shifts driven by scientific innovation, regulatory clarity, and commercialization strategies that prioritize durable outcomes. Breakthroughs in molecular targeting and pathway-specific interventions have expanded the therapeutic toolkit, prompting a transition from broad symptomatic care to disease-modifying approaches that focus on slowing cyst growth and preserving renal function. Consequently, clinical development pathways have become more sophisticated, emphasizing surrogate markers, long-term endpoints, and patient-reported outcomes to capture the multidimensional benefits of new therapies.

Parallel to scientific advances, regulatory agencies have signaled openness to novel endpoints and adaptive trial designs, which has accelerated pathway optimization for leading candidates. This regulatory evolution, combined with payer interest in outcome-linked reimbursement, is encouraging biopharma sponsors to design integrated evidence-generation plans that include post-approval real-world studies. The market is also witnessing an expansion of strategic partnerships that align discovery-stage innovation with late-stage development and commercialization capabilities, enabling faster scalability and broader geographic reach.

Operationally, the shift toward specialty and oral therapies is reshaping distribution models and patient support infrastructure. Manufacturers are refining patient assistance programs, hub services, and digital adherence solutions to support long-term therapy engagement. Taken together, these shifts are redefining competitive dynamics, elevating the importance of differentiated clinical profiles and integrated support services to secure access and sustain patient retention.

Assessing how recent tariff policy adjustments are reshaping sourcing strategies, supply chain resilience, and procurement priorities across the pharmaceutical value chain

United States tariff policy developments announced in 2025 have introduced a new dimension to supply chain planning and procurement cost modeling for pharmaceutical manufacturers and distributors. While finished pharmaceutical products often move under specific trade classifications, tariffs and related import measures targeted at active pharmaceutical ingredients, raw materials, and intermediate chemicals can increase input costs and complicate sourcing strategies. As a result, manufacturers are reevaluating supplier footprints, assessing tariff exposure across product portfolios, and engaging in scenario planning to insulate manufacturing continuity from trade disruption.

In response, industry actors are accelerating diversification of sourcing to reduce dependence on any single geography, increasing local content where feasible, and negotiating terms with contract manufacturers to manage price volatility. These adaptations are also prompting investments in nearshoring and dual-sourcing strategies to improve supply chain visibility and responsiveness. Moreover, tariff-driven cost pressures can influence pricing discussions with payers and health systems, particularly for high-cost specialty therapies where margins are carefully managed.

Beyond direct cost impacts, the tariffs have catalyzed broader strategic conversations about onshore capacity for critical APIs and packaging materials, regulatory harmonization, and public-private collaborations to safeguard essential pharmaceutical supply chains. Companies are therefore balancing the economics of reshoring with the capital and time required to scale domestic manufacturing, while also lobbying for tariff exclusions and policy relief that recognize the public health implications of supply chain disruption. In short, tariff developments in 2025 have amplified the imperative for resilient procurement models and proactive policy engagement across the industry.

A multidimensional segmentation-driven analysis revealing where clinical differentiation, distribution pathways, and care settings create strategic opportunities and operational imperatives

A segmented view of the therapeutics landscape reveals differentiated opportunities and operational imperatives across drug classes, administration routes, disease phenotypes, distribution channels, and care settings. Based on Drug Type, analysis covers Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, mTOR Inhibitors, Somatostatin Analogs, and Vasopressin Receptor Antagonists, each of which carries distinct mechanisms of action, safety profiles, and development trajectories that influence positioning and clinical utility. Based on Mode of Administration, the study distinguishes between Intravenous or Injectable therapies and Oral regimens, highlighting contrasts in patient adherence considerations, infusion infrastructure requirements, and reimbursement dynamics.

Based on Disease Type, the research differentiates Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease, noting that diagnostic timelines, genetic counseling needs, and natural history vary between these phenotypes and thereby affect trial design and care pathways. Based on Distribution Channel, the analysis accounts for Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which present unique logistical, regulatory, and patient access considerations that manufacturers must address through channel-specific strategies. Based on End-User, the market is examined across Clinics, Homecare Settings, and Hospitals, underscoring differences in treatment initiation, monitoring intensity, and the role of multidisciplinary care teams.

These segmentation lenses together reveal where clinical differentiation, formulation innovation, and commercial models intersect to create pockets of competitive advantage. They also illuminate where evidence generation, provider education, and infrastructure investment are most needed to support therapy adoption and to meet the nuanced needs of patients across the disease spectrum.

How regional regulatory frameworks, clinical research ecosystems, and distribution infrastructures are shaping differentiated access strategies and rollout priorities globally

Regional dynamics are influencing research priorities, regulatory interactions, and access mechanisms in meaningful ways across global markets. In the Americas, clinical trial activity, payer negotiations, and specialty distribution frameworks are driving rapid adoption of novel agents where reimbursement mechanisms accommodate value-based arrangements and specialty pharmacy networks are well established. In Europe, Middle East & Africa, the interplay between centralized regulatory pathways and national reimbursement systems creates a mosaic of market access timelines and evidence requirements, prompting tailored launch strategies and regional evidence generation plans. In Asia-Pacific, diverse healthcare infrastructures and growing clinical research capacity are expanding enrollment pools and creating opportunities for region-specific trials and localized commercialization models.

Geographic differences also shape manufacturing and supply chain decisions, with some regions prioritizing domestic API production and others relying heavily on international trade for pharmaceutical inputs. Regional variations in clinical practice patterns, diagnostic availability, and genetic screening rates can affect uptake and demonstrate the need for regionally adapted educational outreach and payer engagement. Furthermore, regional public health priorities and budgetary constraints influence formulary decisions and the design of patient support mechanisms.

Taken together, a nuanced regional approach that aligns clinical evidence packages with local regulatory expectations, provider behaviors, and distribution realities will be critical for successful global rollouts and for ensuring equitable patient access to emerging therapies.

Insights into how innovation-driven biotechs, multinational pharmaceutical companies, and service providers are collaborating to advance therapies and ensure access across markets

The corporate landscape in this therapeutic area is characterized by a mix of multinational pharmaceutical companies, specialist biotechs, generics manufacturers, and contract service providers, each playing a distinct role in advancing treatments and scaling access. Larger pharmaceutical firms bring experience in late-stage development, regulatory navigation, and global commercialization, which is particularly valuable for therapies requiring complex payer negotiations and specialty distribution. Specialist biotechs often drive innovation at the molecular level, advancing novel mechanisms and niche indications, and then seek partnerships to accelerate late-phase development and market entry.

Generics and biosimilar manufacturers contribute to affordability and long-term access once exclusivity periods end, while contract development and manufacturing organizations provide the production scale and technical expertise needed to manage supply continuity. In addition, patient services vendors, specialty pharmacy operators, and data analytics providers are increasingly integral to commercial success, offering support for adherence, real-world evidence generation, and outcomes tracking.

Across this ecosystem, collaboration models vary from licensing and co-promotion agreements to strategic alliances that combine clinical, regulatory, and commercial capabilities. Companies that align scientific differentiation with robust patient support and supply chain agility are better positioned to navigate payer expectations and to deliver sustained value to clinicians and patients.

Actionable strategic priorities for stakeholders to translate therapeutic innovation into sustainable patient access, resilient supply chains, and payer-aligned evidence generation

Industry leaders must take decisive, evidence-based actions to capitalize on scientific progress while safeguarding access and supply chain resilience. First, prioritize integrated evidence generation that links clinical trial outcomes with real-world data to demonstrate long-term benefits and to support value-based contracting conversations. Second, design commercialization models that are tailored to mode of administration and distribution channel requirements, ensuring that both oral and injectable therapies have clear pathways for initiation, monitoring, and adherence support.

Third, proactively assess and mitigate supply chain exposures by diversifying suppliers of critical APIs and packaging materials, investing in nearshoring where strategically justified, and establishing contingency agreements with contract manufacturers. Fourth, engage early and constructively with payers and regulatory bodies to align on acceptable endpoints, pricing expectations, and post-approval study designs that will facilitate timely access. Fifth, strengthen multi-stakeholder partnerships that bring together clinical experts, patient advocacy organizations, and specialty pharmacies to improve diagnosis rates, optimize treatment protocols, and support patient retention.

Finally, invest in digital health tools and data infrastructure that enable remote monitoring, adherence support, and outcomes measurement. By implementing these prioritized actions, organizations will better position themselves to translate clinical innovation into meaningful patient impact and sustainable commercial outcomes.

A transparent, multi-method research approach combining expert interviews, clinical evidence review, regulatory analysis, and targeted scenario assessments to produce actionable insights

This research synthesis draws on a multi-method approach that integrates primary expert engagement, peer-reviewed literature, regulatory documentation, clinical trial registries, and validated industry databases to ensure a rounded view of clinical, commercial, and policy developments. Primary engagement included structured interviews with clinical thought leaders, payers, supply chain experts, and commercial strategists to capture real-world perspectives on adoption barriers, reimbursement dynamics, and operational constraints. Secondary sources were systematically reviewed to map mechanistic insights, trial outcomes, and regulatory precedents relevant to therapeutic classes under study.

Analytical rigor was supported by cross-validation of data points and triangulation across disparate information streams to mitigate bias and to enhance the robustness of conclusions. Where appropriate, scenario analysis was applied to explore the operational implications of policy shifts, pricing pressures, and supply chain disruptions. The methodology also incorporated segmentation logic to respect differences in drug type, mode of administration, disease phenotype, distribution channel, and end-user setting, ensuring that insights reflect granular variations in clinical and commercial contexts.

Transparency was maintained in documenting data sources and assumptions used for qualitative synthesis, and limitations were acknowledged where evidence was evolving or where published data remained sparse. This methodological framework supports reproducible insight generation and practical applicability for decision-makers seeking to navigate the complex therapeutics landscape.

A strategic summation highlighting the convergence of clinical innovation, evidence-driven access strategies, and operational resilience required to deliver sustained patient impact

As the therapeutic landscape for polycystic kidney disease evolves, stakeholders face an inflection point where scientific opportunity intersects with complex commercial and operational challenges. Advances in targeted therapies and diagnostic stratification are creating pathways to improved patient outcomes, but the realization of clinical benefit depends on coordinated efforts across development, regulatory, payer, and delivery systems. Achieving broad access will require compelling evidence of long-term value, nimble supply chain strategies, and partnerships that align incentives across the care continuum.

The path forward will be shaped by how effectively organizations translate mechanistic breakthroughs into differentiated clinical profiles, how they demonstrate value to payers and providers, and how they build resilient operational models that withstand policy and trade-related disruptions. By focusing on integrated evidence generation, targeted commercialization strategies, and strategic collaborations, stakeholders can convert emerging science into sustainable patient benefit. Ultimately, the combination of rigorous clinical data, proactive policy engagement, and patient-centric support services will determine which therapies deliver meaningful impact at scale.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing use of gene editing approaches such as CRISPR to correct PKD1 and PKD2 mutations in preclinical studies
• 5.2. Rising clinical trials exploring combination therapy targeting mTOR and cAMP signaling pathways for ADPKD management
• 5.3. Growing integration of digital health platforms for remote monitoring of kidney function in PKD patients
• 5.4. Expansion of biomarker-based patient stratification methods to personalize treatment regimens for ADPKD
• 5.5. Regulatory agencies granting accelerated approval pathways for novel PKD therapies under orphan drug designations
• 5.6. Increased investment in small molecule modulators of polycystin protein trafficking to inhibit cyst growth
• 5.7. Emerging utilization of real-world evidence to support safety and efficacy of long-term tolvaptan therapy in ADPKD

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Polycystic Kidney Disease Drugs Market, by Drug Type

• 8.1. Angiotensin II Receptor Blockers
• 8.2. Angiotensin-Converting Enzyme Inhibitors
• 8.3. Calcium Channel Blockers
• 8.4. mTOR Inhibitors
• 8.5. Somatostatin Analogs
• 8.6. Vasopressin Receptor Antagonists

9. Polycystic Kidney Disease Drugs Market, by Mode of Administration

• 9.1. Intravenous (IV) or Injectable
• 9.2. Oral

10. Polycystic Kidney Disease Drugs Market, by Disease Type

• 10.1. Autosomal Dominant Polycystic Kidney Disease
• 10.2. Autosomal Recessive Polycystic Kidney Disease

11. Polycystic Kidney Disease Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Polycystic Kidney Disease Drugs Market, by End-User

• 12.1. Clinics
• 12.2. Homecare Settings
• 12.3. Hospitals

13. Polycystic Kidney Disease Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Polycystic Kidney Disease Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Polycystic Kidney Disease Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Apotex Inc.
  • 16.3.2. Boehringer Ingelheim GmbH
  • 16.3.3. Centessa Pharmaceuticals Limited
  • 16.3.4. Eli Lilly and Company
  • 16.3.5. F. Hoffmann-La Roche AG
  • 16.3.6. Fresenius Kabi AG
  • 16.3.7. Galapagos NV
  • 16.3.8. Kyowa Hakko Kirin Co., Ltd.
  • 16.3.9. Merck & Co., Inc.
  • 16.3.10. Mitsubishi Tanabe Pharma Corporation
  • 16.3.11. Novartis International AG
  • 16.3.12. Otsuka Pharmaceutical Co., Ltd.
  • 16.3.13. Pfizer Inc.
  • 16.3.14. Sanofi S.A.
  • 16.3.15. Teva Pharmaceutical Industries Ltd.
  • 16.3.16. Vertex Pharmaceuticals Incorporated
  • 16.3.17. Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 117. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 119. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 123. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 124. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 128. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 132. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 134. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 140. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 141. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 146. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 148. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 173. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 176. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 177. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 178. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 179. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 180. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 181. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 184. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 185. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 188. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 189. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 190. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 191. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 192. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 193. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 194. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 195. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 196. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 197. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 200. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 201. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 202. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 203. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 204. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 205. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 207. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 208. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 214. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 215. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 216. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 217. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 218. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 219. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 221. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 222. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 223. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 226. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 227. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 228. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 229. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 230. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 231. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 232. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 233. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 234. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 235. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 239. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 240. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 241. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 242. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 243. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 246. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 247. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 250. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 251. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 252. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 253. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 254. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 255. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 257. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 258. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 259. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 262. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 263. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 264. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 265. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 266. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 267. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 269. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 270. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 271. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 274. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 275. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 276. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 277. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 278. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 279. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 280. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 281. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 282. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 286. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 287. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 288. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 289. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 290. UNITED STATES POLY